Is STRO or OMER more profitable?

Omeros has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Sutro Biopharma -395.25% N/A -88.12% Omeros N/A -164.92% 69.41%

Which has higher earnings and valuation, VOR or STRO?

Vor Biopharma has higher earnings, but lower revenue than Sutro Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Sutro Biopharma $102.48M 3.37 -$191.09M -$11.97 N/A

Is VOR or STRO more profitable?

Vor Biopharma has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Sutro Biopharma -395.25% N/A -88.12%

Sutro Biopharma (STRO) Competitors

$20.82 +0.58 (+2.87%)

As of 04:00 PM Eastern

Compare

STRO vs. CGEM, OMER, REPL, VOR, and MGTX

Should you buy Sutro Biopharma stock or one of its competitors? Sutro Biopharma's main competitors and comparable companies include Cullinan Therapeutics (CGEM), Omeros (OMER), Replimune Group (REPL), Vor Biopharma (VOR), and MeiraGTx (MGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sutro Biopharma compare to Cullinan Therapeutics?

Cullinan Therapeutics (NASDAQ:CGEM) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Sutro Biopharma has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cullinan Therapeutics	N/A	N/A	-$219.88M	-$3.10	N/A
Sutro Biopharma	$102.48M	3.37	-$191.09M	-$11.97	N/A

Cullinan Therapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market.

Cullinan Therapeutics presently has a consensus target price of $32.86, indicating a potential upside of 50.79%. Sutro Biopharma has a consensus target price of $47.30, indicating a potential upside of 127.19%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Cullinan Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cullinan Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cullinan Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Cullinan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cullinan Therapeutics	N/A	-52.89%	-48.18%
Sutro Biopharma	-395.25%	N/A	-88.12%

86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 8.6% of Cullinan Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Cullinan Therapeutics had 10 more articles in the media than Sutro Biopharma. MarketBeat recorded 10 mentions for Cullinan Therapeutics and 0 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.89 beat Cullinan Therapeutics' score of 1.29 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cullinan Therapeutics	Positive
Sutro Biopharma	Very Positive

Summary

Sutro Biopharma beats Cullinan Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Omeros?

Sutro Biopharma (NASDAQ:STRO) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Omeros has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.37	-$191.09M	-$11.97	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	14.65

Omeros has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Omeros	N/A	-164.92%	69.41%

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by company insiders. Comparatively, 10.5% of Omeros shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Sutro Biopharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Omeros has a beta of 2.6, suggesting that its share price is 160% more volatile than the broader market.

In the previous week, Omeros had 13 more articles in the media than Sutro Biopharma. MarketBeat recorded 13 mentions for Omeros and 0 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.89 beat Omeros' score of 0.81 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sutro Biopharma	Very Positive
Omeros	Positive

Sutro Biopharma presently has a consensus target price of $47.30, suggesting a potential upside of 127.19%. Omeros has a consensus target price of $38.00, suggesting a potential upside of 102.67%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Sutro Biopharma and Omeros tied by winning 8 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Replimune Group?

Sutro Biopharma (NASDAQ:STRO) and Replimune Group (NASDAQ:REPL) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

In the previous week, Replimune Group had 24 more articles in the media than Sutro Biopharma. MarketBeat recorded 24 mentions for Replimune Group and 0 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.89 beat Replimune Group's score of 0.53 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sutro Biopharma	Very Positive
Replimune Group	Positive

Sutro Biopharma has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.37	-$191.09M	-$11.97	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sutro Biopharma has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

Sutro Biopharma currently has a consensus price target of $47.30, suggesting a potential upside of 127.19%. Replimune Group has a consensus price target of $12.00, suggesting a potential downside of 23.42%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Sutro Biopharma is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Replimune Group has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%. Sutro Biopharma's return on equity of 0.00% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
Replimune Group	N/A	-159.32%	-90.84%

Summary

Sutro Biopharma beats Replimune Group on 12 of the 16 factors compared between the two stocks.

How does Sutro Biopharma compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Sutro Biopharma (NASDAQ:STRO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 1.8% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Vor Biopharma had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 1 mentions for Vor Biopharma and 0 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.89 beat Vor Biopharma's score of 0.94 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Vor Biopharma	Positive
Sutro Biopharma	Very Positive

Vor Biopharma has a beta of 1.71, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.48, meaning that its stock price is 48% more volatile than the broader market.

Vor Biopharma presently has a consensus price target of $43.38, suggesting a potential upside of 91.59%. Sutro Biopharma has a consensus price target of $47.30, suggesting a potential upside of 127.19%. Given Sutro Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Sutro Biopharma is more favorable than Vor Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Vor Biopharma has higher earnings, but lower revenue than Sutro Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Sutro Biopharma	$102.48M	3.37	-$191.09M	-$11.97	N/A

Vor Biopharma has a net margin of 0.00% compared to Sutro Biopharma's net margin of -395.25%.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Sutro Biopharma	-395.25%	N/A	-88.12%

Summary

Sutro Biopharma beats Vor Biopharma on 6 of the 11 factors compared between the two stocks.

How does Sutro Biopharma compare to MeiraGTx?

Sutro Biopharma (NASDAQ:STRO) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Sutro Biopharma has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, MeiraGTx has a beta of 1.27, suggesting that its stock price is 27% more volatile than the broader market.

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 1.8% of Sutro Biopharma shares are owned by company insiders. Comparatively, 7.4% of MeiraGTx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

MeiraGTx has a net margin of 19.87% compared to Sutro Biopharma's net margin of -395.25%. MeiraGTx's return on equity of 283.85% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-395.25%	N/A	-88.12%
MeiraGTx	19.87%	283.85%	29.39%

In the previous week, MeiraGTx had 4 more articles in the media than Sutro Biopharma. MarketBeat recorded 4 mentions for MeiraGTx and 0 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.89 beat MeiraGTx's score of 1.36 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Sutro Biopharma	Very Positive
MeiraGTx	Positive

Sutro Biopharma currently has a consensus price target of $47.30, suggesting a potential upside of 127.19%. MeiraGTx has a consensus price target of $26.17, suggesting a potential upside of 84.40%. Given Sutro Biopharma's higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than MeiraGTx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
MeiraGTx	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

MeiraGTx has lower revenue, but higher earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$102.48M	3.37	-$191.09M	-$11.97	N/A
MeiraGTx	$81.39M	16.74	-$114.20M	$0.71	19.99

Summary

MeiraGTx beats Sutro Biopharma on 9 of the 15 factors compared between the two stocks.

Get Sutro Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STRO vs. The Competition

Export

Metric	Sutro Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$335.60M	$3.97B	$7.13B	$12.68B
Dividend Yield	N/A	3.61%	2.54%	10.96%
P/E Ratio	-1.74	11.92	272.61	25.04
Price / Sales	3.37	1,327.68	612.80	95.93
Price / Cash	N/A	44.06	28.78	36.03
Price / Book	-3.34	16.89	11.06	6.25
Net Income	-$191.09M	-$22.72M	$3.47B	$348.99M
7 Day Performance	-2.89%	-2.35%	-0.84%	-2.42%
1 Month Performance	-13.86%	11.57%	7.15%	2.94%
1 Year Performance	142.91%	54.76%	24.74%	13.69%

Sutro Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STRO Sutro Biopharma	3.2745 of 5 stars	$20.82 +2.9%	$47.30 +127.2%	+136.1%	$335.60M	$102.48M	N/A	240	Positive News
CGEM Cullinan Therapeutics	3.0676 of 5 stars	$21.82 +0.6%	$32.86 +50.6%	+192.7%	$1.40B	N/A	N/A	30
OMER Omeros	4.0691 of 5 stars	$19.32 +0.3%	$38.00 +96.7%	+351.7%	$1.39B	N/A	15.09	210	Insider Trade
REPL Replimune Group	2.2293 of 5 stars	$14.71 -0.4%	$11.86 -19.4%	+183.3%	$1.39B	N/A	N/A	210
VOR Vor Biopharma	1.8753 of 5 stars	$22.71 -2.8%	$43.38 +91.0%	-42.9%	$1.38B	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STRO) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sutro Biopharma (STRO) Competitors

STRO vs. CGEM, OMER, REPL, VOR, and MGTX

How does Sutro Biopharma compare to Cullinan Therapeutics?

Summary

How does Sutro Biopharma compare to Omeros?

Summary

How does Sutro Biopharma compare to Replimune Group?

Summary

How does Sutro Biopharma compare to Vor Biopharma?

Summary

How does Sutro Biopharma compare to MeiraGTx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sutro Biopharma (STRO) Competitors

STRO vs. CGEM, OMER, REPL, VOR, and MGTX

How does Sutro Biopharma compare to Cullinan Therapeutics?

Which has stronger valuation & earnings, CGEM or STRO?

Which has more risk and volatility, CGEM or STRO?

Do analysts recommend CGEM or STRO?

Is CGEM or STRO more profitable?

Do institutionals & insiders believe in CGEM or STRO?

Does the media refer more to CGEM or STRO?

Summary

How does Sutro Biopharma compare to Omeros?

Which has higher valuation and earnings, STRO or OMER?

Is STRO or OMER more profitable?

Do institutionals and insiders hold more shares of STRO or OMER?

Which has more volatility & risk, STRO or OMER?

Does the media prefer STRO or OMER?

Do analysts prefer STRO or OMER?

Summary

How does Sutro Biopharma compare to Replimune Group?

Does the media favor STRO or REPL?

Which has preferable earnings & valuation, STRO or REPL?

Do insiders and institutionals hold more shares of STRO or REPL?

Which has more volatility and risk, STRO or REPL?

Do analysts rate STRO or REPL?

Is STRO or REPL more profitable?

Summary

How does Sutro Biopharma compare to Vor Biopharma?

Do institutionals & insiders hold more shares of VOR or STRO?

Does the media prefer VOR or STRO?

Which has more volatility & risk, VOR or STRO?

Do analysts recommend VOR or STRO?

Which has higher earnings and valuation, VOR or STRO?

Is VOR or STRO more profitable?

Summary

How does Sutro Biopharma compare to MeiraGTx?

Which has more risk and volatility, STRO or MGTX?

Do institutionals and insiders hold more shares of STRO or MGTX?

Is STRO or MGTX more profitable?

Does the media favor STRO or MGTX?

Do analysts rate STRO or MGTX?

Which has higher earnings and valuation, STRO or MGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRO vs. The Competition

Sutro Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools